Therapeutics: Protein kinase B (AKT; AKT1; PKB; PKBA); CDC-like kinase 2 (CLK-2); SH3 and multiple ankyrin repeat domains 3 (SHANK3; PROSAP2; SPANK-2)

Patient sample and rodent studies suggest inhibiting CLK-2 or activating AKT could help treat Phelan-McDermid syndrome (PMDS) or autism in patients harboring SHANK3 mutations. Levels of T308-phosphory...